Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is Baxter International an Underrated Healthcare Investment Play?

2026-02-06
Baxter International is in turnaround mode, but a recent dividend decision will keep many investors away.

Reassessing Baxter International (BAX) Valuation After A Mixed Return Profile And 2026 Outlook Focus

2026-02-04
What recent performance data suggests for Baxter International (BAX) Baxter International (BAX) has been on many investors’ radars after a mixed stretch, with a 1-month return of 2.1%, a 3-month return of 10.9%, and a 1-year total return decline of 35.5%. At a last close of US$19.91, the company carries a value score of 4, supported by reported annual revenue of US$11.0b and a net income loss of US$344.0m. This combination helps frame the risk and reward trade-off that investors are currently...

How Investors May Respond To Baxter (BAX) Earnings Miss, Dividend Cut And Novum IQ Setback

2026-02-04
Baxter International recently reported third-quarter 2025 results with adjusted earnings per share ahead of expectations but revenue of US$2.84 billion below forecasts, alongside a dividend cut, hurricane-related production disruptions, and continued shipment holds on its Novum IQ infusion pumps following safety concerns. At the same time, Baxter advanced its position in the growing advanced wound closure market by launching a next-generation Artiss fibrin sealant spray for large-area burn...

How Recent Moves Are Rewriting The Story For Baxter International (BAX)

2026-02-04
Baxter International’s latest price target work keeps the fair value estimate clustered around US$23.13 per share, with only a small adjustment to the discount rate and revenue growth assumptions. This signals that recent information has not materially reshaped the core story in the models behind that number. Street research is still split between the low US$20s and US$30 range, but there is clear focus on how upcoming Q4 results and the 2026 outlook might either confirm or challenge the...

Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions

2026-02-03
Medical device leaders counter tariff pressures with innovation, as AI adoption and aging demographics support long-term growth.

Here’s What Hit Baxter (BAX) in Q4

2026-02-03
Pzena Investment Management recently released its fourth-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. The fourth quarter was defined by strong AI momentum and continued market dominance by mega-cap stocks. In this environment, Pzena Focused Value Strategy underperformed the Russell 1000® Value Index, delivering a net return of […]

4 Medical Product Stocks to Watch From a Challenging Industry (Revised)

2026-02-03
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

2026-02-02
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Advanced Wound Closure Market size & share revenue was valued at approximately USD 18.47 Billion in 2025 and is expected to reach USD 19.68 Billion in 2026 and is expected to reach around USD 32.54 Billion by 2035, at a CAGR of 6.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson (Ethi

4 Medical Product Stocks to Watch From a Challenging Industry

2026-02-02
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Does Baxter International (BAX) Offer Opportunity After Prolonged Share Price Weakness?

2026-02-01
If you are wondering whether Baxter International's share price still reflects its underlying business, the key question is whether the stock now offers value or just looks cheap on the surface. The stock recently closed at US$20.07, with returns of 1.2% over 7 days and 2.9% over 30 days. However, over the longer term it shows a 37.2% decline over 1 year, 53.6% over 3 years and 71.1% over 5 years, which raises very different questions about risk and opportunity. Recent coverage around Baxter...